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Infection prevention and control of 
Clostridium difficile: a global review of 
guidelines, strategies, and recommendations 
Background Clostridium difficile is the leading cause of health care–
associated infections. Given the high incidence of C. difficile infection 
(CDI) and the lack of primary prevention through immunization, 
health care professionals should be aware of the most current guid-
ance, as well as strengths and limitations of the evidence base under-
pinning this guidance.
Methods We identified publicly available national or organizational 
guidelines related to CDI infection and prevention control (IPC) pub-
lished between 2000 and 2015 and for any health care setting through 
an internet search using the Google search engine. We reviewed CDI–
targeted IPC recommendations and describe the assessment of evi-
dence in available guidelines.
Results We identified documents from 28 countries/territories, main-
ly from acute care hospitals in North America, the Western Pacific, 
and Europe (18 countries). We identified only a few specific recom-
mendations for long–term care facilities (LTCFs) and from countries 
in South America (Uruguay and Chile), South East Asia (Thailand), 
and none for Africa or Eastern Mediterranean. Of 10 IPC areas, anti-
microbial stewardship was universally recognized as essential and 
supported by high quality evidence. Five other widely reported 
“strong” recommendations were: effective environment cleaning (in-
cluding medical equipment), case isolation, use of personal protec-
tive equipment, surveillance, and education. Several unresolved and 
emerging issues were documented and currently available evidence 
was classified mainly as of mixed quality.
Conclusion Our review underlines the need for targeted CDI IPC 
guidelines in several countries and for LTCFs. International harmon-
isation on the assessment of the evidence for best practices is needed 
as well as more robust evidence to support targeted recommenda-
tions.
C. difficile is the leading cause of health care–associated infections (HAI) 
worldwide affecting especially the elderly and hospitalised patients [1–5]. 
The burden of CDI remains under–recognized and challenges associated 
with case detection hinder prevention. It was estimated that in 2011, over 
450 000 CDI cases occurred in the United States and 172 000 in Europe 
[6,7]. Mounting evidence of the rising importance of CDI in other regions, 
such as Asia [8,9] and Latin America [10,11] contributes to concerns 
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about the wide–ranging reach of CDI morbidity [6,12,13]. 
Given the high incidence of CDI and the lack of primary 
prevention through immunization, health care profession-
als should be aware of the most current guidance, as well 
as strengths and limitations of the evidence base underpin-
ning this guidance.
There are wide variations in the availability or levels of im-
plementation of effective Infection Prevention and Control 
(IPC) measures for CDI. A national survey in Canada iden-
tified an extensive lack of antimicrobial stewardship pro-
grammes, less than 25% of the 33 participating hospitals 
[14] in 2005. More recently, attention was drawn to the 
lack of clinical awareness and testing [15], disparities in the 
strength of recommendations across different IPC guide-
lines [16], and the lack of knowledge on the independent 
effects of common IPC strategies [17–19]. As guidelines are 
useful tools to promote coordinated IPC efforts, a detailed 
documentation of current published strategies has the po-
tential to highlight commonalities and discrepancies in rec-
ommended practices. A comprehensive overview of pub-
lished guidelines also has the potential to inform the 
decision–making of infection control stakeholders at the 
national, provincial, and institutional level and help re-
searchers in targeting current gaps in the literature.
In this review, we describe the availability of documents 
that outline recommendations and actions for the preven-
tion and control of CDI. We present a structured assess-
ment of key elements of CDI–IPC strategies together with 
their strengths of recommendation and levels of evidence 
across 10 IPC areas followed by a discussion of current is-
sues. A summary of unresolved issues to inform future re-
search is also provided.
Search strategy and selection process
Two reviewers (EB, TF) conducted an internet search (with 
the Google search engine) in July 2015 of publicly avail-
able national or organizational guidelines, related to CDI 
control (published between 2000 and 2015 and for any 
health care setting). Keywords used included “difficile” 
“clostridium difficile”, “policy”, “strategies”, “control”, “pre-
vention”, “recommendation”, “guideline”, and “protocol.” 
Guidelines were defined as documents with systematically 
developed statements to assist practitioners and patients to 
make decisions about appropriate health care for specific 
clinical circumstances [20] or documents guidance from 
professional entities, which described IPC guidance and 
strategies for CDI. We retrieved the most updated and/or 
comprehensive documents principally from national de-
partments/ministries of health and the websites of profes-
sional societies including those members of the Interna-
tional Federation of Infection Control. No language 
restrictions were applied. GoogleTranslate was used as the 
main translation tool for documents in languages other 
than English, Spanish, and Romanian (which were read 
directly by reviewers). Manuals containing generic HAI 
guidelines and documents with guidelines for treatment or 
policies of individual hospitals were not included. Struc-
tured abstraction of the recommendations from guidelines 
was conducted independently by the two reviewers and 
compared for 10 areas relevant to CDI–IPC, drawing from 
previous work [16,21,22].
Presentation of results
For each area, we first present a brief description of the 
guidance identified, followed by a summary of the quality 
of evidence assessment and strength of recommendations 
identified in the guidelines (see below). We then present a 
discussion of current literature supporting recommenda-
tions or an overview of relevant issues.
Quality of evidence and strength of 
recommendations
Seven documents graded the quality of evidence [23–29] 
(four ranking systems used) and nine provided strength of 
recommendations [23,24,27–33] (five ranking systems). 
The data quality categories of the ranking systems were 
broadly similar, and were grouped in three descriptive cat-
egories (high, medium, and low). The strength of recom-
mendations for implementation were grouped into the fol-
lowing categories: strong recommendation (two levels 
differentiated by quality of supporting evidence); recom-
mended, consideration, and legal requirement. Strategies were 
also classified as Basic, Special (ie, likely to reduce risk but 
concerns exist about undesirable outcomes), or Unresolved 
Issue/Area of Research/Inconclusive in one guideline [26]. 
(See Appendix S2 in Online Supplementary Document).
RESULTS
Availability of guidance for CDI–IPC
Globally, 42 documents with targeted IPC recommenda-
tions for CDI were identified (Figure 1). These documents 
described guidance from 28 different countries/territories 
in 4 WHO regions. A summary of the main characteristics 
of these documents is available in Appendix S1 in Online 
Supplementary Document.
In North America, 2 Canadian government advisory docu-
ments [34,35] and 4 documents from US–based profes-
sional bodies (3 guidelines [23,26,27], and an implemen-
tation guide [36]) were identified. In Europe, documents 
from government and professional organizations from 18 
countries [24,25,28,30–33,37–54] and by the European 
Centre for Disease Control (ECDC) [29] were reviewed. 
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Eleven guidelines reported grading for either the quality of 
evidence or strength of recommendation for implementa-
tion in their statements [23–33]. In the Western Pacific re-
gion, descriptive advisory reviews of guidelines by govern-
mental agencies [55–58] and two professional groups 
(Australasian Society for Infectious Disease (ASID)/Austra-
lian Infection Control Association (AICA)) were included 
[59,60]. In South America, government guidelines from 
Chile [61,62] and Uruguay (draft) [63] were identified. In 
South East Asia, a document by a Thai professional orga-
nization which combines a review of the literature with a 
short section (6 items) on the prevention of CDI [64] was 
identified. No documents were identified from the Eastern 
Mediterranean or Africa regions.
CDI–IPC strategies in non–acute care 
facilities
No specific recommendations were identified for CDI pa-
tients in skilled–nursing facilities, such as residential care 
and nursing homes, outpatient care, rehabilitation, and 
long–term care facilities (LTCFs). C. difficile–targeted IPC 
strategies mainly drew from evidence from acute care set-
tings. Four guidance documents were specific to LTCFs 
and in other nine, recommended strategies were combined 
with guidance for acute hospitals. Relevant issues and chal-
lenges for the prevention of CDI in LTCFs were highlight-
ed including: the vulnerable health status of residents 
which may pose difficulties in maintaining precautions (eg, 
cognitively impaired patients [58], frequent stool inconti-
nence [36]); the placement of CDI cases in LTCFs in shared 
rooms due the limited number of single rooms [36]; and 
the lack of convenient hand–washing facilities [27,35]. The 
importance of surveillance, monitoring of outbreaks, and 
communication between ambulance services and staff in 
acute care facilities (when residents with CDI needed to be 
transported) was discussed [58], especially in the light of 
the under–recognized burden of CDI and imperfect adher-
ence to IPC guidelines in LTCFs (including private and vol-
untary nursing homes) [25,31].
Figure 1. Geographic distribution of CDI-targeted IPC guidance reviewed. Countries with documents included in the review are 
colored by WHO regions (see legend left). Regional guidance by professional organizations (ECDC and ASID) are not depicted. 
Other results from the web–based search are also shown with different symbols (see legend right). Documents from countries with 
empty red circles were not examined as could not be translated (Poland) or full text could not be obtained (Malta, Latvia) but have 
previously been assessed [16].
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Recommended strategies within IPC areas
Approaches to reduce transmission and to minimise host 
susceptibility by prudent antibiotic use were widely report-
ed, but differences in other areas existed, as shown in Table 
1, Table 2 and Table 3.
IPC Area 1: Pharmacological methods
Antibiotics: The strong risk posed by antibiotics for CDI was 
mentioned in the majority of documents (Table 1 and Ta-
ble 2). Recommendations included: to minimise use 
among patients already at increased risk, stop any CDI–in-
citing antimicrobials such as broad–spectrum cephalospo-
rins (3rd generation), penicillins, fluoroquinolones, and 
clindamycin in suspected cases [23,24,29], or promoting 
the implementation of antibiotic stewardship programmes 
(ASP). Few documents detailed the specific roles and re-
sponsibilities of different stakeholders (eg, infection control 
teams, administration, pharmacists, microbiologists, clini-
cians, and senior management). Detailed overviews of pro-
cedures recommended for establishing, implementing, and 
monitoring ASP in different settings were also reported 
[25,31,32,34–36].
Evidence assessment: Concordance between the evidence 
grades given in different guidelines was high. Guidelines 
strongly recommended the cautious use of antibiotics to 
prevent CDI and the evidence grade was awarded the high-
est levels.
Discussion: Although one guideline established that avail-
able evidence on the effect of ASP did not fully meet all cri-
teria for the highest level of quality (research has mainly 
relied on before–and–after studies) [26], judicious use of 
antibiotics was widely recognized as essential for CDI pre-
vention. Despite the limitations in the evidence, the ben-
eficial effect of prudent antibiotic use on CDI is noteworthy. 
A recent systematic review and meta–analysis quantified 
the effect of both persuasive (education and guidance) and 
restrictive (approval required, removal) ASP for CDI [65]. 
A significant protective role (overall risk ratio 0.48, 95% 
confidence interval CI 0.38–0.62) was found, with the 
strongest evidence for restrictive programmes and those 
with the longest duration. Similarly, another review found 
that ASP and environmental disinfection were the two most 
important IPC for CDI in hospitals [18].
ASP require adequate resourcing (human and financial), 
thus they need to be well designed, integrated, audited, and 
monitored as parts of larger HAI IPC strategies [66]. Fur-
thermore, the potential effects of utilizing antibiotics con-
sidered to be non–CDI–inciting, such as gentamicin, have 
been raised as important considerations to monitor [67]. 
Globally, an assessment of ASP showed that although strat-
egies within programmes in 67 countries vary significantly, 
commonalities do exist and important challenges demand 
concerted worldwide action, such as the continuous pro-
spective measurement of well–defined outcomes and ap-
propriate resourcing [68].
Probiotics: Several guidelines recognized the suggested use 
of probiotics for the prevention of CDI. Nine documents 
labeled it as an area of research or declared no recommenda-
tion can be made. Others mentioned probiotics within de-
scriptions related to CDI treatment and their potential role 
in preventing recurrences of CDI, but offered no formal 
recommendation (Table 1 and Table 2).
Evidence assessment: One guideline [23] stated that moder-
ate evidence existed supporting the use of two probiotics 
to decrease the incidence of antibiotic–associated diarrhea, 
but quality of evidence was low for CDI.
Discussion: Recently, a group of experts proposed a state-
ment recommending utilization of two specific probiotics 
(L. acidophilus CL1285 and L. casei LBC80R) for CDI [69]. 
Although systematic reviews and meta–analyses report a 
protective effect of probiotics [70–72] and some publica-
tions reviewed here mention their potential use, studies 
exploring the contribution of probiotics to CDI prevention 
are largely limited by high heterogeneity between studies, 
high risk of bias, inadequate study power or significant lev-
els of missing outcome data [26]. In light of these limita-
tions in the evidence base, guidelines that systematically 
graded evidence stated that current scientific evidence on 
probiotics’ effect on CDI is insufficient to recommend their 
use for IPC.
Gastric acid suppressants: Guidance indicates that proton 
pump inhibitors (PPI) and histamine receptor antagonists 
(H2RA) should be considered as important risk factors for 
CDI but conclude that the issue remains unresolved with no 
official recommendation for CDI (Table 1).
IPC Areas 2–4: Transmission based control 
measures – patient–care related strategies
Isolation of cases
Isolation of CDI cases, confirmed and suspected, was wide-
ly recommended together with the use of en–suite bath-
rooms or individual bedpans. Guidelines also recommended 
cohorting CDI patients (Table 1 and Table 2), if necessary. 
The benefits and considerations stated, beyond preventing 
the spread of C. difficile spores, included effective allocation 
of human and economic resources and the development of 
specific expertise among dedicated staff managing the iso-
lated patient/cohort. Maintaining contact precautions until 
at least after diarrheal episodes have stopped (most com-
monly for 48 hours or longer) was generally recommended. 
However, extended contact precautions until the discharge 
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Challenges to elucidate the effect of isolation procedures as 
a means to prevent transmission of CDI will be influenced 
by each facility’s ability to detect CDI cases promptly, avail-
ability of isolation rooms, and duration of measures. None-
theless, recent attempts have been made to provide an es-
timate of the effect of isolating CDI cases. For instance, a 
retrospective cohort study reported a 43% (95% CI 7–65%) 
drop in C. difficile acquisition rate in a facility with single–
rooms in its ICU wards compared to multi–bed rooms 
[74]. An increased risk of recurrence (odds ratio OR: 3.77 
95% CI 1.37–10.35) among previously cohorted patients 
has also been reported [75]. Although shedding of C. dif-
ficile spores and evidence of contamination after resolution 
of diarrhea has been found [76,77], the effect of longer iso-
lation periods and isolation on the incidence of CDI or risk 
of transmission remains poorly understood.
Hand hygiene and adequate use of PPE is vital for HAI pre-
vention. Although the use of ABHRs is inadequate to elim-
inate C. difficile spores and hand washing is preferred (a 
message conveyed in most guidelines), concerns exist 
about compliance and detrimental effects of mixed instruc-
tions for hand hygiene [73]. Recently, a study found that 
compliance with WHO–recommended practices by health 
care workers caring for patients with CDI was observed to 
be approximately 60–70%, with no hand hygiene conduct-
ed inside isolation rooms. A higher compliance was ob-
served for the use of gloves (~ 85–90%) and gowns (~ 88–
97%) [78]. Clearly more research is needed, especially for 
the effect of different hand hygiene practices on CDI inci-
dence during endemic periods [22], but a stronger empha-
sis on the use of gloves has been underscored as an impor-
tant, economical, and potentially more effective measure 
to prevent C. difficile transmission [79].
IPC Area 5–6: transmission control – 
environmental contamination
All documents addressed the importance of environmental 
cleaning to prevent C. difficile transmission. Chlorine–based 
and sporicidal agents were the most commonly recom-
mended solutions. The use of other technologies, including 
UV light or hydrogen peroxide vapor, was discussed and 
highlighted as an unresolved issue [80,81]. The vast major-
ity of guidelines advised that medical equipment used for 
CDI cases should be patient–dedicated or disposable, where 
possible. Commonly reported potential sources of contam-
ination included items that come into direct contact with 
patients (blood pressure cuffs, stethoscopes, thermometers) 
or are at risk of contamination due to soiling (beds, furni-
ture, sinks, floor, curtains, etc.). Thorough cleaning of all 
equipment used after caring for CDI cases or that entered 
the isolation/cohort room (including dishes and laundry) 
was also advised. Recommendations explicitly addressing 
of the CDI case [26,60,63] were also advised. Administrative 
support and communication were underscored as key fac-
tors given that isolation of cases can incur managerial diffi-
culties and costs.
Personal protective equipment (PPE)
Adequate use of PPE by health care workers caring for CDI 
cases, particularly gloves and gowns, was consistently and 
strongly recommended as an important precautionary mea-
sure in all documents. Use of PPE by visitors was recom-
mended, but knowledge on the beneficial effect was labeled 
as an unresolved issue [26].
Hand hygiene
The importance and challenges associated with effective 
hand hygiene in the context of C. difficile IPC were dis-
cussed in all documents. Special attention was drawn to 
limitations of disinfection hand with alcohol–based hand 
rubs (ABHR) as they are non–sporicidal and do not remove 
C. difficile spores from contaminated hands. Guidance on 
best practices varied and included the preferential use of 
soap and water when caring for patients with CDI, espe-
cially during outbreaks, raising awareness and warning 
health care providers about the limitations of ABHRs 
[38,48,49], or stressing the WHO hand hygiene recom-
mendations and the primary use of ABHR to prevent con-
fusing messages [60].
Evidence assessment: The reported quality of the evidence 
on the protective effect of isolation/cohorting and on the 
optimum duration of contact precautions for CDI ranged 
from low to high. Evidence was graded of high quality for 
outbreak situations, in one guideline [23].
The use of gloves and gowns was strongly recommended, 
but the quality of available evidence was deemed mixed.
The evidence on the effect of different hand hygiene prac-
tices was reported to be of moderate quality and the effica-
cy and usefulness of disinfection over hand–washing for 
hand hygiene purposes was reported as an area of contro-
versy [26]. These differences in reporting the value of hand 
hygiene practices stem from research showing that hand–
washing with soap and water is the most efficacious way to 
remove C. difficile spores. However, while the use of ABHR 
alone is not effective, its use does not appear to be detrimen-
tal in terms of impacting directly on CDI rates [73].
Discussion: It is noteworthy that there is a reliance on evi-
dence from studies of multidrug–resistant organisms to 
prevent CDI through patient–care strategies [29] and a pau-
city in studies that have evaluated their efficacy during en-
demic periods [17,22]. Additional studies are necessary to 
further clarify the effects of the use of ABHR on CDI and 
make a more robust conclusion.
www.jogh.org •  doi: 10.7189/jogh.06.020410	 5	 December 2016  •  Vol. 6 No. 2 •  020410
V
IE
W
PO
IN
TS
PA
PE
RS
Balsells et al.
the role of electronic or rectal thermometers were identified 
in 17 documents (Table 1, Table 2 and Table 3).
Evidence assessment: Despite the high level of agreement 
across guidelines on the use of sporicidal chlorine–based so-
lutions, the optimum type of solution used for environmen-
tal cleaning of C. difficile was considered to remain as an area 
of controversy [26]. The strongly recommended use of pa-
tient–dedicated or of single–use devices was common and 
guidelines concurred that currently available evidence is of 
moderate quality (individual randomly–controlled trials and 
non–randomized studies). The quality of evidence in sup-
port of replacement of electronic for single–use disposable 
thermometers was graded as high/moderate quality.
Discussion: Published data on the effect of environmental 
decontamination with solutions currently recommended 
to prevent CDI transmission “have not been consistent” and 
the effect of bleach has only been demonstrated in out-
break situations [82] and in combination with other IPC 
measures. Additionally, concerns about their corrosive 
properties and potentially harmful effect on the health 
and safety of staff need to be weighed carefully against the 
benefits of their use [83]. Beyond the physical environ-
ment, attention has been drawn to other potential sourc-
es of contamination. For instance, whole genome se-
quence–based studies have the potential to clarify issues 
about patient–to–patient transmission including the role 
of asymptomatic C. difficile colonised patients, but more 
research is needed [77].
IPC Area 7: education of staff and patients/
visitors
Education was defined as instructions, information, train-
ing, educational campaigns or workshops for health care 
facility workers, patients, or visitors on any aspect of CDI–
IPC. Over half of the guidelines recommended an educa-
tion component for education of staff (health care, clean-
ing, or auxiliary personnel), patients and/or visitors (Table 
1, Table 2 and Table 3).
Evidence assessment: Education was strongly recommended 
across guidelines, with the quality of evidence for its effect 
being graded high to low.
Discussion: The effect of educational programmes as CDI–
IPC interventions has not been fully assessed. However, 
studies have reported a worrying gap in the knowledge 
about CDI among health care workers [84–86] and the 
suboptimal quality of educational materials for patients 
[87]. Lack of clinical suspicion was identified as a key fac-
tor leading to under– and misdiagnosis of CDI cases in Eu-
rope [15], which can hinder adequate and timely imple-
mentation of IPC measures.
IPC Area 8–9: case detection and 
surveillance
Surveillance was recommended at various levels in guide-
lines: from national, including LTCF/NH [25,31,32] to at 
least facility–based level with a minimum of hospital–onset 
health care–associated cases [26,62]. Documents providing 
information on surveillance recommended the use of stan-
dardised case definitions. Most guidelines included a state-
ment or clarifications that discouraged conducting test of 
cure. Over half of the guidelines explicitly recommended 
against testing or treating asymptomatic patients (Table 3).
Regarding testing policies and laboratory assays, the use of 
standardised criteria (eg, Bristol stool chart [25,31,38]) or 
definitions (≥3 unformed stools in ≤24 consecutive hours 
[26]) was reported to identify adequate samples to be test-
ed. However, other documents described, generally, the 
importance of testing “unformed/diarrheal stools”. Addi-
tional strategies included no testing of infants (mainly in 
Europe), no (or limited) repeat testing. General descrip-
tions were also identified for the use of molecular typing 
methods for severe cases or during outbreaks. Table 1 in-
cludes information on case detections methods in docu-
ments reviewed. Notably, guidelines reported toxin enzyme 
immunoassays as not suitable as stand–alone, molecular 
tests were strongly recommended as standard test in the 
US [23], and multi–step algorithms were generally de-
scribed in other documents.
Evidence assessment: The quality of evidence to not conduct 
a test of cure after CDI’s symptoms resolution was awarded 
the highest score in Europe, but moderate and low scores 
in recent guidelines by US–based organizations [23, 26]. 
Guidelines agree that, currently, there is no evidence to 
support the detection or routine screening of C. difficile 
among asymptomatic patients, with published studies be-
ing of moderate and low quality. The strength of recom-
mendation for CDI–targeted surveillance systems ranged 
from strong to conditional, and of legal character. Manda-
tory or legal components regarding reporting of cases were 
described for the UK, Ireland, and Hungary, compared to 
recommended laboratory–based sentinel and facility–
based voluntary systems in other countries.
Discussion: Prompt case detection is vital for the implemen-
tation of IPC strategies for CDI. Concerted efforts to better 
understand and address the burden of CDI, such as for the 
development of case definitions for surveillance [88] and 
improved understanding of laboratory tests’ limitations 
[89] and diagnosis procedures have been promoted since 
the mid–2000s.
The use and implications of differential CDI case detection 
methods have been described in recent studies [6,15,90,91]. 
In Europe, it was shown that testing policies varied widely, 
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Table 2. CDI–IPC: pharmacological agents and transmission control (patient–care related)*
ipC arEa
Pharmacological methods Contact precautions Personal protection Hand hygiene
Antibiotic 
stewardship
Probiotics Single 
room
Cohort-
ing
Duration (based on 
cases’ diarrhea)†
Gloves Gowns
Acute care – North America:
Canada (2013)    R or NI   S/W (preferably at point–of–care or as 
soon as sink is available or ‡) ABHR
APIC (2013)  Inconclusive   R>48h   S/W and ABHR, or ABHR (endemic)
SHEA/IDSA (2014) (II, Basic) UI (III, 
Basic)
(Basic) R or R>48h (Basic), if 
‡: D (III Special)
(II Basic), 
UI
(III Basic), 
UI
WHO 5 moments, if ‡, S/W, ABHR
AJG (2013) Strong (H) RNM 
Strong (L)
Strong 
(H)
Strong 
(H)
R; Strong (H) Strong 
(M)
Strong 
(M)
S/W Strong (M)
Acute care – Europe:
ECDC (2008) IA (1a) RNM IB 
(1b, 2b)
IB 
(1b, 4)
R>48h; II (4) IB 
(1b, 2b)
IB 
(1a, 1b, 4)
S/W (not ABHR alone), IB 
(2a, 2b, 2c)
Austria (2007) IA (1a) Tx, R–CDI, 
PS
IB 
(1b, 2b)
IB 
(1b, 4)
R>48h; II (4) IB 
(1b, 2b)
IB 
(1a, 1b, 4)
S/W and ABHR (limitations), IB 
(2a, 2b, 2c)
Belgium (2008)    R>48 or 72h; (Level 2) (Level 1) (Level 1) S/W and ABHR
Bulgaria (2009)    R>48h   S/W
Cyprus (2014)  RNM   R>48h   S/W, ABHR after S/W (limitations)
Denmark (2011)   R>48h   S/W, ABHR (limitations)
Finland (2007)   R>48h   S/W then ABHR (limitations)
France (2010)    R   S/W then ABHR (limitations)
Germany (2009)    R>48h   S/W (preferred and if soiling), ABHR
Hungary (2011) IA, IB, IC Tx, R–CDI IB IB R>72h II IB IB S/W and ABHR; IB
Ireland (2014)  Tx, R–CDI (C–D) (D) R/R>48h (D) (A) (D) S/W (A)
Italy (2009) IA (1a) RNM IB 
(1b, 2b)
IB 
(1b, 4)
R>48h II (4) IB 
(1b, 2b)
IB 
(1a, 1b, 4)
S/W; not ABHR alone; IB, (2a, 2b, 2c)
Lithuania (2011)    R>48h   S/W
Luxembourg (2007)   R   S/W then ABHR
Macedonia (2014)  Tx, R–CDI     S/W, ABHR (limitations)
Netherlands (2011)    R>48h   S/W, (ABHR not added value)
Romania  Tx, R–CDI   R>48 or 72h   S/W, no AB–solutions
England (2008) B RNM2013 B B R>48h C A A–B S/W then ABHR A
N. Ireland (2008)   R>72h§   S/W (ABHR limitations)
Scotland (2014) IA, IB, II Tx, R–CDI: 
insufficient 
evidence
IB IB R>48h II IB IB S/W (not ABHR alone), IB (staff); 
II (visitors)
Acute care – Western Pacific:
ASID/AICA (2011)  RNMPS   R>48h, if ‡:D   WHO 5 moments, Primary use 
ABHR, If soiled: S/W
Hong Kong (2014)  AR   R or NI   WHO recommendations, S/W
Japan (2008)      S/W
New Zealand (2013) ¶  R>48 h§   WHO 5 moments, S/W or ABHR, if 
‡: S/W and ABHR
Singapore (2013) ¶     S (antiseptic)/W or ABHR
Acute care – South East Asia:
Thailand (2009)  Tx, R–CDI  S/W
Acute care – Latin America:
Chile (2012–13)    R or D   S/W
Uruguay (2015)    D   S/W
Long term care:
SHEA (2002) A–B (I, II, III) RNM B (III)  R A (I) RNM S/W or antimicrobial agent ; B (III)
Canada (2013)    R or NI   S/W (preferably at point–of–care or 
where sink is available, or if ‡), ABHR
Germany (2012)   R>72h   S/W and ABHR
APIC – Association for Professionals in Infection Control and Epidemiology, SHEA – The Society for Healthcare Epidemiology of America, IDSA – In-
fectious Diseases Society of America, AJG – American Journal of Gastroenterology, ECDC – European Centre for Disease Prevention and Control, ASID 
– Australasian Society for Infectious Diseases, AICA – Australian Infection Control Association, S/W – soap/water, ABHR – alcohol–based hand rub, AR 
– area of research, PS – position statement, UI – Unresolved issue, R–CDI – prevention of recurrent CDI, Tx – treatment, RNM – recommendations can-
not be made
* If grading of evidence available: Strength of recommendations bold font; (Quality of evidence). Type of documents and scope of included docu-
ments vary: eg, Denmark, Finland, and the Netherlands focus on hygiene. Table adapted from Martin et al [16]. Strong recommendations: IA–IB, A–B, 
Level 1, I–II; To be considered: II, C, Level 3, III. Quality of evidence grading: High: (1a–1c), (H), (I), (A); Medium–Low: (2a–4), (M–L), (B), (II–III), 
(B–C); Expert opinion: 5; D.; Legal: IC. A tick () indicates recommendation available.
† Lifting of contact precaution measures: case diarrheal status: resolved (R) or non–infectious (NI) or period (hours) after symptoms resolved, (D) Dis-
charge.
‡ Outbreak.
§ Bristol Stool chart.
¶ Information available/No detailed recommendation.
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Table 3. CDI–IPC strategies for transmission control (environment), education, and case detection*
ipC arEa
Environmental 
cleaning†
Medical equipment Education Case detection Surveillance‡ Out-
break
Patient–ded-
icated or 
single–use
No electronic 
(E) or rectal 
(R) thermom-
eters
Staff Visitors/
patients
No test of 
cure
No testing/
treating 
asymptomatic 
patients
Acute care – North America:
Canada (2013) S, C [1]  E      
APIC (2013) C§  E, R      
SHEA/IDSA (2014) S§, C (III) UI  E (III, Basic) UI (III, Basic) (III, Basic) (II) (III Basic) 
AJG (2013) S§, C; Strong (H) Strong (M) E; Strong (M) Strong (M) Strong 
(M)
Strong; Test: 
(High); Tx: (Low)
Conditional 
(M)

Acute care – Europe:
ECDC (2008) S, C [1]; IB (2b, 2c) IB (1b) E; IA (1b, 2b) IA (1a, 2b, 4, 5) IA (1a) IB (2b, 3b, 4) IB (2b, 3b, 4, 5) 
Austria (2007) S; IA [1]–PS IB (1b, 2c, 4) R; IA (1b, 2b) IA; (1a, 2b, 4, 5) If¶ IA (1a) IB (2b, 3b, 4) IB (2b, 3b, 4, 5) 
Belgium (2008) C [1,2] (Level 1–2)     
Bulgaria (2009) S, C, not alcohol  
Cyprus (2014) C [1]  R  
Denmark (2011) C [1]  R 
Finland (2007) C [1,2]      
France (2010) S, C  **     
Germany 2009) S, C, peracetic acid       
Hungary 2011) S, C; IB–IC  E; IA IA IA IB IB–IC 
Ireland (2014) C [1] (D)  (D) (C–D) (D) (D) (B) 
Italy (2009) C [1]; IB (2b, 2c) IB (1b) E,R; IA (1b, 2b) IA (1a, 2b, 4, 5) IA (1a) IB (2b, 3b, 4) IB (2b, 3b, 4, 5) 
Lithuania (2011) C    
Luxembourg (2007) S, C  
Macedonia (2014) S, C  
Netherlands (2011) C   
Romania D, S,C [1], other††  E   
England (2008) C [1]; B B E A–C B Mandatory B 
N. Ireland (2008) C or D/C [1]      Mandatory 
Scotland (2014) C [1]; IB IB E; IA IA IA IB Mandatory 
Acute care – Western Pacific:
ASID/AICA (2011) S, C [1], if ¶: FM, 
1–step: D/S
 R     Min: Facility 
Hong Kong (2014)  **    Facility 
Japan (2008)  
N. Zealand (2013) S, D/C [1]   
Singapore (2013) S, C [1]  E, R
Acute care – South East Asia:
Thailand (2009) S, C, other ††  
Acute care – Latin America:
Chile (2012–13) S, C [1,2]     Facility based 
Uruguay (2015) C [1,2]       
Long term care:
SHEA (2002) S, C; B (II) B (III) E; A (II) B (III) B (II) Tx: A (I) B (III)
Canada (2013) S, C [1]  E      
Germany (2012) S: no alcohol; 
ammonium
   
APIC – Association for Professionals in Infection Control and Epidemiology, SHEA – The Society for Healthcare Epidemiology of America, IDSA – In-
fectious Diseases Society of America, AJG – American Journal of Gastroenterology, ECDC – European Centre for Disease Prevention and Control, ASID 
– Australasian Society for Infectious Diseases, AICA – Australian Infection Control Association, UI – Unresolved issue
*Type of documents and scope of included documents vary: eg, guidelines from the Netherlands and Denmark focus on hygiene. Table adapted from 
Martin et al [16]. If grading of evidence available: Strength of recommendations bold font; (Quality of evidence). A tick () indicates recommenda-
tion available. Strong recommendations: IA–IB, A–B, Level 1, I–II; to be considered: II, C, Level 3, III. Quality of evidence: High: (1a–1c), (H), (I), 
(A); Medium–Low: (2a–4), (M–L), (B), (II–III), (B–C); Expert opinion: (5); (D); Legal: (IC).
†Cleaning solutions/methods: C: Chlorine–based; S: Sporicidal; D: Detergent; FM: Fluorescent markers. [Chlorine–based concentration] 1: at least 1000 
ppm; 2: 5000 ppm
‡Some information obtained from other sources (eg, Department of Health website).
§EPA–approved.
¶Outbreak.
**Information available/No detailed recommendation.
††Alkaline glutaraldehyde, ethylene.
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a factor that contributed to a large number of CDI cases 
being missed on a daily basis. A notable exception was the 
UK, where both under– and misdiagnosis is uncommon, 
as national guidelines have been introduced to standardise 
laboratory diagnosis including confirmatory procedures 
[15,43]. In the US, 43% of 120 laboratories surveyed used 
molecular assays as first– or second–line for diagnosis of 
CDI, similarly to the percentage using enzyme immunoas-
say tests alone (42%) [91]. In this survey, use of molecular 
tests was more likely to be accompanied by higher rejec-
tion rates for unnecessary testing (ie, formed stools, test for 
cure, or duplicates within 7 days). Although faster molec-
ular methods have the potential to reduce isolation costs 
and treatment delays as compared to multi–step algo-
rithms, the unknown proportion of cases diagnosed by 
high–sensitive molecular tools who may not be CDI cases 
needs careful consideration as inconsistent results have 
been found on the impact confirmatory procedures can 
have on clinical practice [89,92]. False positives can lead 
to unnecessary implementation of IPC measures and treat-
ment (which in itself increases the risk of developing CDI 
due antibiotic use) and distort the epidemiological picture 
of burden of disease.
IPC Area 10: outbreak management
Over half of documents included a labeled and separate sec-
tion for recommendations during outbreaks or periods of 
increased incidence [23-25, 28–30, 32–37, 44, 45, 49, 54, 
60, 62, 63]. Case definitions of outbreaks were not clearly 
reported in most guidelines. Surveillance systems were rec-
ognized as an essential tool to identify and monitor out-
breaks [26]. Two formats for case definition of CDI outbreaks 
were identified:
•  Definitions based on exceeding triggers based on local 
CDI epidemiology (hospital or ward’s, as available) 
[25,34,35] with the addition of a specified period of 
time criteria [29] (eg, expected incidence of CDI ex-
ceeded for 1 [62] or 2 [32,63] weeks in a specific area).
•  Defined thresholds and criteria (eg, 3 or more cases of 
hospital–acquired CDI for 2 weeks in a specific area 
[44]; 2 or more cases caused by the same strain over a 
defined period and related in time and place [31]).
IPC recommendations in different guidelines for outbreaks 
ranged in detail and depth but most convey a common 
message: during CDI outbreaks, all IPC measures should 
be enhanced. Additional key recommendations during out-
breaks included:
•  Promoting timely communication between healthcare 
workers and other infection prevention and control 
efforts.
•  Assessing antibiotic prescribing and environmental 
cleaning practices to prevent further use of high–risk 
CDI antibiotics and ensure high quality control of de-
contamination.
•  Collecting samples for molecular typing of CDI cases 
to determine if outbreak is associated with hyper–vir-
ulent strains (eg, 027, 176, or 078) (Table 1).
•  As resources and logistics allow, setting up dedicated 
administrative systems to manage admissions and 
staff to CDI–affected wards.
Documents lacking a clear section for IPC of outbreaks, 
drew attention to specific strategies by differentiating best 
practices during outbreaks as compared to endemic peri-
ods (eg, environmental cleaning – increase frequency [52] 
or hand washing practices [58] – consider restricting hand 
hygiene to handwashing with soap and water) (Table 1, 
Table 2 and Table 3).
Prevention of CDI and the need for 
coordinated strategies
Implementation of general HAI IPC strategies is crucial to 
minimise risk of CDI and, as this review shows, several tar-
geted efforts for C. difficile exist. Furthermore, clear and 
consistent guidance is needed to integrate CDI prevention 
efforts into larger HAI–control programmes effectively. We 
reviewed documents with CDI–IPC recommendations in 
28 countries and found a general consensus on a selected 
number of strongly recommended strategies: prudent use 
of antimicrobials, adequate environmental cleaning with 
agents with sporicidal effects, time–sensitive isolation, and 
barrier methods for staff including gowns and gloves. How-
ever, we also some noted important variations.
Differences in availability of strategies in documents were 
found, which can be explained by differences in the scope 
and type of documents, the recognized CDI burden, health 
care systems infrastructures, and national legislation re-
quirements. However, varying or imprecise guidance sug-
gests that there is still room for further primary studies but 
also greater harmonisation of CDI–IPC guidelines, namely 
in the assessment of the quality of the evidence. For in-
stance, clear recommendations on most accurate labora-
tory algorithms can be provided rather than descriptions 
of available methods. Such guidance has the potential to 
promote best and standardised practices but also raise 
awareness of the limitations of the alternatives and inform 
allocation resource for IPC. Optimum CDI case detection 
methods are changing and updated guidelines will soon 
become available [93]. Due to the systematic methods used 
to develop guidelines by professional bodies, such as ECDC 
and SHEA/IDSA, these are important resources from which 
to draw information for establishing or updating national 
guidance and achieve a greater international alignment, yet 
allowing for national matters to be taken into consider-
ation.
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In light of previous widespread of C. difficile hyper–virulent 
strains, a clear section with detailed measures for endemic 
and epidemic periods should be available in guidelines, to 
address the burden of CDI effectively. We found a general 
absence of such distinction in half of the documents, as 
well as differential appraisal of the quality of evidence for 
key strategies (eg, the effect of isolation during epidemics 
was graded mixed to high). Our review underlines previ-
ous findings of a lack of uniformity in the assessment of 
evidence in guidelines [16] and suggests a need for stron-
ger international alignment of CDI–IPC guidance guided 
by an objective assessment of the literature.
Agreement about best practices across guidelines has been 
indispensable for advancing efforts in an integrated man-
ner on the role of antibiotics, which could also enable co-
ordinated efforts in other areas. The CDC’s recent recom-
mendations for both acute health facilities [66] and LTCFs 
[94] are significant resources informed by CDI–IPC efforts. 
Future studies on the effect of the introduction of ASP and 
close monitoring of the effect of previously considered “low 
risk” antibiotics are required to continue informing our un-
derstanding of antibiotics and CDI. It is imperative that 
coordinated efforts are undertaken to elucidate strengths 
and weaknesses of the evidence base and update guidance 
and convey clear CDI–IPC statements for other areas. For 
instance, beneficial effects of probiotics for CDI are not sup-
ported by high quality studies, as described previously. We 
identified consensus on the recommendation from guide-
lines with systematic assessment of the literature, but also 
ambiguous guidance in descriptive documents. C. difficile’s 
epidemiology continues to evolve and review of guidelines 
by qualified local professional bodies is necessary to rec-
ommend best practices, based on the strongest quality of 
research. Such exercises have the potential to support the 
development of context–appropriate tools for different 
stakeholders, such as checklists, cleaning regimes, or edu-
cation packages for health care workers (an example [95]), 
cleaning staff, and patients.
The paucity of guidelines pertinent to different types of 
health care settings is concerning due to the increased in-
cidence of CDI in the last 20 years. It is also of concern that 
the overall effect of interventions in high risk settings such 
as LTCFs is under–recognized, where suboptimal compli-
ance to recommendations has previously been identified 
[37], where C. difficile is a common pathogen causing diar-
rhea [96], and where over–prescription of antibiotics is 
prevalent. In the USA, over 4 million Americans reside in 
LTCFs and a substantial majority (70%) are at increased 
risk of CDI due to high use of antibiotics in this setting 
(40–75% prescribed incorrectly) [94]. It is important to 
adapt guidance based on acute care settings experiences 
with evidence from interventions in LTCF and nursing 
homes [96,97]. We recommend high quality studies on the 
effect of IPC strategies in nursing homes and LTCFs are 
synthesized, appraised, and as possible, incorporated into 
guidelines to inform targeted IPC of CDI efforts.
Beyond single and targeted strategies, organizational ac-
countability, mentioned in few of the guidelines, demands 
particular attention as it is essential for development of 
country–specific implementation of strategies. Stakehold-
ers’ roles and responsibilities, including that of govern-
ments and senior management staff, need to be clear and 
informed by evidence relevant to national structures. For 
instance, in the UK, investigations on significant recent out-
breaks have resulted in reports with recommendations 
which inform the roles of responsibilities of care and man-
agement staff [98,99]. Recognition of gaps in the system 
enabled development of new guidance, such as procedures 
to capture C. difficile–associated deaths, and detailed meth-
ods to strengthen coordination of IPC teams.
Bundles for prevention and control of CDI
Available evidence indicates that multi–faceted pro-
grammes of CDI prevention have the potential to be sub-
stantially effective and cost–saving. In the UK, CDI–IPC 
strategies include legislative support (ie, mandatory nation-
al surveillance systems and wider organizational account-
ability, including defined roles and responsibilities for all 
groups of health care staff and senior management), hand 
and environmental hygiene campaigns, and optimised test-
ing/diagnosis techniques [7]. In addition to cost savings, 
quality improvement in health care and patient safety are 
also major priorities. Based on this comprehensive IPC ap-
proach, the estimated cost reduction associated with a de-
crease in the number of CDI cases (5–15%) ranged from 
GBP 4.65–13.94 million [100]. In the United States, a re-
cent study estimated that if basic recommendations by the 
SHEA/IDSA were introduced nationally, over 5 million CDI 
cases among patients 65 years of age or older would be 
averted during a 5–year period. This reduction in number 
of cases would result in US$ 2.5 billion of savings [19]. Of 
note, this study adopted a conservative economic model 
which estimated the cost of isolation until discharge, rath-
er than until symptom resolution.
Emerging topics and the need for more 
research
Box 1 presents a summary of research questions as identi-
fied in the documents reviewed. The need for innovative 
prevention technologies and more effective cleaning solu-
tions were discussed. High quality studies on the effect of 
interventions such as the use of case notification systems, on 
the potential roles of different health care workers in detec-
tion of cases and implementation of IPC, and on unresolved 
issues were recognized as important areas of research.
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Notably, there is a need for higher quality and comparable 
evidence on the attributable effects of existing CDI preven-
tion measures, especially during endemic periods 
[17,18,22]. Adequate surveillance and improved detection 
of cases require critical attention, as our review found that 
differences in approaches exist. Although best practices are 
still a matter of debate, well–established, resourced, and 
audited surveillance systems for CDI are essential. Surveil-
lance supported by consistent, clear, and cost–effective lab-
oratory testing practices (including rejection policies) has 
the potential to inform the effect of CDI–targeted IPC and 
novel interventions, such as “bundles” or vaccines. Costs 
associated with implementation of effective surveillance 
and case detection methods should be assessed in light of 
the benefits for patients’ safety and care. Further, adequate 
reporting of aspects of infectious control measures is need-
ed in future studies to identify optimum CDI control pro-
grammes (eg, dedicated personnel time, laboratory sup-
plies, and outbreak investigations) [18]. We echo previous 
recommendations that future studies should adhere to the 
Area of controversy
•  Ability of diluted sodium hypochlorite or other sporicidal 
agents used for environmental decontamination [26].
• Reliance on alcohol–based hand hygiene products [26].
•  Management, including detection or isolation, of patients 
colonized (asymptomatic) with C. difficile without CDI his-
tory [26,45].
Unresolved issues (UI) or other (O) strategies identified in 
guidelines
Case detection, including roles of different health care workers 
in CDI–IPC
Notification systems or laboratory–based alert systems
O: Role of community pharmacists [25], medical equipment 
and health care staff in ambulances [31,58].
UI: Alert for changes in the rate, complications, or severity of 
CDI that may indicate the introduction of new strains [29] or 
for cases readmitted or transferred) [26,45].
UI: Role of nurses (standing orders or nurse–driven protocols) 
[26].
Transmission control
O: Use of bleach or cleaning wipes for disinfection or Fluores-
cent markers or adenosine triphosphate to measure organic 
material [25,34–36].
O: Development of protocols for disinfection of equipment and 
environment and monitoring [34,35].
O: Visitor and staff management: visitors/staff with diarrhea 
should not visit patients in the hospital [45].
O: Facility design (eg, selection of materials for surfaces, ade-
quate number of hand washing facilities) [34,35].
UI: Use of gown and gloves by visitors [26].
UI: Use of soap that contains antiseptic substances [45].
Box 1 CDI prevention and infection control emerging topics and future steps
UI: No–touch disinfection technologies as component of IPC 
strategies (UV, hydrogen peroxide vapor) [26].
Pharmacological agents
UI: Use of Vaccines and immunotherapies [32].
UI: Role of probiotics as primary prophylaxis [26].
UI: Restriction of gastric acid suppressants [25,26].
Education
UI: On–going assessment of CDI knowledge and intensified 
CDI education among health care and cleaning personnel [26].
LTCF Research questions and relevant issues
Notification of CDI among LTCF residents to relevant staff in 
the acute care setting if transfer is necessary [25,58].
Attention to CDI cases’ activities and placement (shared rooms) 
[35].
Monitoring compliance with infection prevention and control 
guidance and adequate implementation of strategies (includ-
ing diarrheal, outbreaks, and waste management and access to 
laboratory services) [37].
The following research questions [27]
•  Are older patients truly at increased risk of acquiring C. dif-
ficile or CDI? If so, what determinants are responsible?
•  Are therapeutic strategies equally effective in older popula-
tion and in younger adults?
•  Are differences between risks for CDI outbreaks explained 
by variations in antibiotic exposure or are there other factors?
•  What are the variables that influence transmission of C. dif-
ficile between residents in long–term care settings?; What is 
the role of environment, and patient care practices?
•  What level of environmental cleaning, hand hygiene, or glove 
use is optimal to limit transmission of the organism?
•  Are infection control recommendations different for patients 
with diarrhoea compared with those without?
ORION statement to be able to synthesize evidence in a 
more transparent and consistent manner [15,18,19], thus 
support greater harmonisations of CDI–targeted IPC ef-
forts.
Understanding the prophylactic effects of pharmacological 
methods is an area of great interest for CDI–IPC. Passive 
immunization to toxins TcdA and TcdB has been tested for 
the prevention of recurrences. Given its high cost and tran-
sient protection, active immunization is currently viewed 
as a potentially more cost–effective strategy. Both toxoid–
based and peptide vaccines are currently under develop-
ment [101,102]. Another developing area of research is the 
prevention of recurrent episodes and severe disease out-
comes with more effective antibiotics. Recently, a 3–4 fold 
decrease in CDI recurrence and 28–day mortality was ob-
served in hospitals with routine use of fidaxomicin as first–
line treatment, and at a greater rate than in hospitals with 
selective use of this antibiotic [103]. As burden of disease 
associated with CDI remains high, cost–effective pharma-
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cological methods to prevent incident, recurrent, or severe 
outcomes represent a key area for targeted IPC.
Limitations
The present review has limitations. We relied on electron-
ic search methods of publicly available documents. We also 
relied on translation to examine the full text of several 
guidelines and one document could not be translated [51]. 
However, we identified and reviewed a large number of 
documents obtained through comprehensive searches un-
dertaken by two reviewers. While the interpretation of 
some of the guidelines’ through our review may be influ-
enced by language restrictions, the majority of documents 
included in analysis are in languages that reviewers man-
age fluently. Finally, we did not review compliance with 
national guidelines, treatment of CDI, or strategies not 
within the 10 selected IPC areas as it was beyond the scope 
of this review.
CONCLUSIONS
Our review findings indicate a widespread awareness of the 
importance of CDI–IPC guidelines but there are significant 
gaps which still exist. The review identified published 
guidelines from regions which have experienced an in-
crease in the incidence of CDI in recent years (such as the 
USA, Canada, Europe and the Western Pacific) and also 
countries where epidemiology of C. difficile has not been 
extensively examined (such as Thailand, Chile, and Uru-
guay). However, we did not retrieve IPC guidelines for CDI 
from several countries in South America, South East Asia, 
and Europe and none from Africa and Eastern Mediterra-
nean. We reviewed documents for Bulgaria, Hungary, 
Macedonia, Poland, and Romania, which were not includ-
ed in a previous assessment of European guidelines. Our 
review also found only a few clear and specific recommen-
dations for LTCFs and nursing homes, mainly from North 
America, Europe and Western Pacific. This represents a 
large gap in an important global infection control area. 
Thus, this review adds to the existing collection of IPC 
guidance availability for C. difficile [16,104] and provides 
a global overview of approaches and challenges for those 
interested in developing or revising protocols for CDI pre-
vention and control.
This review of guidelines also highlights the need for great-
er international harmonisation in the assessment of the ev-
idence underpinning IPC recommendations for CDI and 
for more research. Key strategies strongly and consistently 
recommended in published guidelines included: ASP, en-
vironmental and medical devices cleaning, use of protective 
equipment (gloves and gowns), and prompt isolation of 
CDI cases. Surveillance and education were also strongly 
recommended. High quality research, other than for high–
risk antibiotics, is still needed. Our review shows that 
much of the evidence underpinning the guidance was grad-
ed of medium to low level, by the use of 4 different rank-
ing schemes (assessed only in guidelines from the USA and 
Europe) and different primary studies were considered in 
different guidelines. The recommended establishment of 
surveillance and standardised monitoring systems will help 
develop comparable studies and better evaluate the effect 
of interventions on CDI incidence in the future.
Our review of unresolved issues and inconsistently identi-
fied strategies indicates that implementation of CDI–IPC 
measures variations between world regions exist, mainly for 
hand hygiene and case detection approaches (including lab-
oratory testing policies). Country–specific organizational 
accountability roles require key attention for successful IPC 
efforts and control outbreaks associated with C. difficile. 
Strategies on the use of probiotics, gastric acid suppressants, 
and on the potential roles of IPC stakeholders could benefit 
from clear recommendations statements. Studies that pro-
vide more robust estimates of interventions’ effects in high–
risk settings such as LTCF and of emerging IPC technolo-
gies, such as vaccines, have the potential to inform 
coordinated efforts and advise priority setting exercises.
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